Clinical Trial Update: Safety and Efficacy Study of VIS649 for IgA Nephropathy [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of VIS649 for Immunoglobulin A nephropathy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glomerular Disease
• Immunoglobulin Nephropathy

Drugs mentioned

• VIS649

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Immunoglobulin A Nephropathy, Glomerular Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-11-21